Trial Profile
A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Neuroblastoma; Osteosarcoma; Rhabdoid tumour; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms NORTH
- 05 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 17 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 28 May 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT04897880).